A common mechanism for CFTR potentiators

Journal of General Physiology

Volumn 149, Issue 12, 2017, Pages 1105-1118

  Yeh, Han I ^a   Sohma, Yoshiro ^a,b   Conrath, Katja ^c   Hwang, Tzyh Chang ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c GALAPAGOS NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHENOL DERIVATIVE; CHLORIDE CHANNEL STIMULATING AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; PROTEIN BINDING; QUINOLONE DERIVATIVE;

AGONISTS; ANIMAL; BINDING SITE; CHANNEL GATING; CHO CELL LINE; CRICETULUS; DRUG EFFECT; GENETICS; HAMSTER; HUMAN; METABOLISM;

AMINOPHENOLS; ANIMALS; BINDING SITES; CHLORIDE CHANNEL AGONISTS; CHO CELLS; CRICETINAE; CRICETULUS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; ION CHANNEL GATING; PROTEIN BINDING; QUINOLONES;

EID: 85036616784     PISSN: 00221295     EISSN: 15407748     Source Type: Journal    
DOI: 10.1085/jgp.201711886     Document Type: Article

References (61)

1. Aleksandrov, A.A., L. Aleksandrov, and J.R. Riordan. 2002. Nucleoside triphosphate pentose ring impact on CFTR gating and hydrolysis. FEBS Lett. 518:183-188. https ://doi .org /10 .1016 /S0014-5793(02)02698-4
2. Barry, P.J., N. Ronan, and B.J. Plant. 2015. Cystic fibrosis transmembrane conductance regulator modulators: The end of the beginning. Semin. Respir. Crit. Care Med. 36:287-298. https :// doi .org /10 .1055 /s-0035-1546821
3. Bear, C.E., C.H. Li, N. Kartner, R.J. Bridges, T.J. Jensen, M. Ramjeesingh, and J.R. Riordan. 1992. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell. 68:809-818. https ://doi .org /10 .1016 /0092-8674(92)90155-6
4. Berg, J., J. Tymoczko, and L. Stryer. 2002. Chemical bonds in biochemistry. In Biochemistry. Fifth edition. WH Freeman, New York. Section 1.3
5. Bompadre, S.G., Y. Sohma, M. Li, and T.C. Hwang. 2007. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. J. Gen. Physiol. 129:285-298. https ://doi .org /10 .1085 /jgp .200609667
6. Bompadre, S.G., M. Li, and T.C. Hwang. 2008. Mechanism of G551D-CFTR (cystic fibrosis transmembrane conductance regulator) potentiation by a high affinity ATP analog. J. Biol. Chem. 283:5364-5369. https ://doi .org /10 .1074 /jbc .M709417200
7. Cai, Z., A. Taddei, and D.N. Sheppard. 2006. Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl-channel. J. Biol. Chem. 281:1970-1977. https ://doi .org /10 .1074 /jbc .M510576200
8. Chaves, L.A.P., and D.C. Gadsby. 2015. Cysteine accessibility probes timing and extent of NBD separation along the dimer interface in gating CFTR channels. J. Gen. Physiol. 145:261-283. https :// doi .org /10 .1085 /jgp .201411347
9. Cholon, D.M., N.L. Quinney, M.L. Fulcher, C.R. Esther Jr., J. Das, N.V. Dokholyan, S.H. Randell, R.C. Boucher, and M. Gentzsch. 2014. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci. Transl. Med. 6:246ra96. https ://doi .org /10 .1126 /scitranslmed .3008680
10. Csanády, L. 2000. Rapid kinetic analysis of multichannel records by a simultaneous fit to all dwell-time histograms. Biophys. J. 78:785-799. https ://doi .org /10 .1016 /S0006-3495(00)76636-7
11. Csanády, L., and B. Töröcsik. 2014. Structure-activity analysis of a CFTR channel potentiator: Distinct molecular parts underlie dual gating effects. J. Gen. Physiol. 144:321-336. https ://doi .org /10 .1085 /jgp .201411246
12. Csanády, L., P. Vergani, and D.C. Gadsby. 2010. Strict coupling between CFTR's catalytic cycle and gating of its Cl-ion pore revealed by distributions of open channel burst durations. Proc. Natl. Acad. Sci. USA. 107:1241-1246. https ://doi .org /10 .1073 / pnas .0911061107
13. Cui, L., L. Aleksandrov, Y.-X. Hou, M. Gentzsch, J.-H. Chen, J.R. Riordan, and A.A. Aleksandrov. 2006. The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating. J. Physiol. 572:347-358. https ://doi .org /10 .1113 /jphysiol .2005 .099457
14. Cui, L., L. Aleksandrov, X.B. Chang, Y.X. Hou, L. He, T. Hegedus, M. Gentzsch, A. Aleksandrov, W.E. Balch, and J.R. Riordan. 2007. Domain interdependence in the biosynthetic assembly of CFTR. J. Mol. Biol. 365:981-994. https ://doi .org /10 .1016 /j .jmb .2006 .10 .086
15. Dalemans, W., P. Barbry, G. Champigny, S. Jallat, K. Dott, D. Dreyer, R.G. Crystal, A. Pavirani, J.P. Lecocq, and M. Lazdunski. 1991. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature. 354:526-528. https ://doi .org /10 .1038 /354526a0
16. Du, K., and G.L. Lukacs. 2009. Cooperative assembly and misfolding of CFTR domains in vivo. Mol. Biol. Cell. 20:1903-1915. https :// doi .org /10 .1091 /mbc .E08-09-0950
17. Du, K., M. Sharma, and G.L. Lukacs. 2005. The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat. Struct. Mol. Biol. 12:17-25. https ://doi .org /10 .1038 /nsmb882
18. Eckford, P.D., C. Li, M. Ramjeesingh, and C.E. Bear. 2012. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATPindependent manner. J. Biol. Chem. 287:36639-36649. https :// doi .org /10 .1074 /jbc .M112 .393637
19. Goodman, L.S. 2011. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th edition. McGraw-Hill, New York. 77 pp
20. Gunderson, K.L., and R.R. Kopito. 1994. Effects of pyrophosphate and nucleotide analogs suggest a role for ATP hydrolysis in cystic fibrosis transmembrane regulator channel gating. J. Biol. Chem. 269:19349-19353
21. Gunderson, K.L., and R.R. Kopito. 1995. Conformational states of CFTR associated with channel gating: The role of ATP binding and hydrolysis. Cell. 82:231-239. https ://doi .org /10 .1016 /0092-8674(95)90310-0
22. Hadida, S., F. Van Goor, J. Zhou, V. Arumugam, J. McCartney, A. Hazlewood, C. Decker, P. Negulescu, and P.D.J. Grootenhuis. 2014. Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator. J. Med. Chem. 57:9776-9795. https ://doi .org /10 .1021 /jm5012808
23. Hwang, T.C., and D.N. Sheppard. 1999. Molecular pharmacology of the CFTR Cl-channel. Trends Pharmacol. Sci. 20:448-453. https :// doi .org /10 .1016 /S0165-6147(99)01386-3
24. Hwang, T.C., and D.N. Sheppard. 2009. Gating of the CFTR Clchannel by ATP-driven nucleotide-binding domain dimerisation. J. Physiol. 587:2151-2161. https ://doi .org /10 .1113 /jphysiol .2009 .171595
25. Hwang, T.C., F. Wang, I.C. Yang, and W.W. Reenstra. 1997. Genistein potentiates wild-type and delta F508-CFTR channel activity. Am. J. Physiol. 273:C988-C998
26. Jih, K.Y., and T.C. Hwang. 2013. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc. Natl. Acad. Sci. USA. 110:4404-4409. https ://doi .org /10 .1073 /pnas .1215982110
27. Jih, K.Y., Y. Sohma, and T.C. Hwang. 2012. Nonintegral stoichiometry in CFTR gating revealed by a pore-lining mutation. J. Gen. Physiol. 140:347-359. https ://doi .org /10 .1085 /jgp .201210834
28. Jih, K.Y., W.Y. Lin, Y. Sohma, and T.C. Hwang. 2017. CFTR potentiators: From bench to bedside. Curr. Opin. Pharmacol. In press. https ://doi .org /10 .1016 /j .coph .2017 .09 .015
29. Kopeikin, Z., Y. Sohma, M. Li, and T.C. Hwang. 2010. On the mechanism of CFTR inhibition by a thiazolidinone derivative. J. Gen. Physiol. 136:659-671. https ://doi .org /10 .1085 /jgp .201010518
30. Kopeikin, Z., Z. Yuksek, H.Y. Yang, and S.G. Bompadre. 2014. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. J. Cyst. Fibros. 13:508-514. https ://doi .org /10 .1016 /j .jcf .2014 .04 .003
31. Lin, W.Y., K.Y. Jih, and T.C. Hwang. 2014. A single amino acid substitution in CFTR converts ATP to an inhibitory ligand. J. Gen. Physiol. 144:311-320. https ://doi .org /10 .1085 /jgp .201411247
32. Lin, W.Y., Y. Sohma, and T.C. Hwang. 2016. Synergistic potentiation of cystic fibrosis transmembrane conductance regulator gating by two chemically distinct potentiators, ivacaftor (VX-770) and 5-nitro-2-(3-phenylpropylamino) benzoate. Mol. Pharmacol. 90:275-285. https ://doi .org /10 .1124 /mol .116 .104570
33. Liu, F., Z. Zhang, L. Csanády, D.C. Gadsby, and J. Chen. 2017. Molecular structure of the human CFTR ion channel. Cell. 169:85-95.e8. https ://doi .org /10 .1016 /j .cell .2017 .02 .024
34. Ma, T., J.R. Thiagarajah, H. Yang, N.D. Sonawane, C. Folli, L.J. Galietta, and A.S. Verkman. 2002. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxininduced intestinal fluid secretion. J. Clin. Invest. 110:1651-1658. https ://doi .org /10 .1172 /JCI0216112
35. Miki, H., Z. Zhou, M. Li, T.C. Hwang, and S.G. Bompadre. 2010. Potentiation of disease-associated cystic fibrosis transmembrane conductance regulator mutants by hydrolyzable ATP analogs. J. Biol. Chem. 285:19967-19975. https ://doi .org /10 .1074 /jbc .M109 .092684
36. Ostedgaard, L.S., O. Baldursson, and M.J. Welsh. 2001. Regulation of the cystic fibrosis transmembrane conductance regulator Clchannel by its R domain. J. Biol. Chem. 276:7689-7692. https :// doi .org /10 .1074 /jbc .R100001200
37. Pedemonte, N., N.D. Sonawane, A. Taddei, J. Hu, O. Zegarra-Moran, Y.F. Suen, L.I. Robins, C.W. Dicus, D. Willenbring, M.H. Nantz, et al. 2005. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol. Pharmacol. 67:1797-1807. https ://doi .org /10 .1124 /mol .105 .010959
38. Quinton, P.M., and M.M. Reddy. 1991. Regulation of absorption in the human sweat duct. Adv. Exp. Med. Biol. 290:159-170
39. Riordan, J.R., J.M. Rommens, B. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielenski, S. Lok, N. Plavsic, J.L. Chou, et al. 1989. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science. 245:1066-1073. https ://doi .org /10 .1126 /science .2475911
40. Rosser, M.F.N., D.E. Grove, L. Chen, and D.M. Cyr. 2008. Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: Folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2. Mol. Biol. Cell. 19:4570-4579. https ://doi .org /10 .1091 /mbc .E08-04-0357
41. Rowe, S.M., and A.S. Verkman. 2013. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb. Perspect. Med. 3:a009761. https ://doi .org /10 .1101 /cshperspect .a009761
42. Rowe, S.M., S. Miller, and E.J. Sorscher. 2005. Cystic fibrosis. N. Engl. J. Med. 352:1992-2001. https ://doi .org /10 .1056 /NEJMra043184
43. Sohma, Y., and T.C. Hwang. 2015. Cystic Fibrosis and the CFTR Anion Channel. In Handbook of Ion Channels. CRC Press, Boca Raton, FL, 627-648. https ://doi .org /10 .1201 /b18027-48
44. Stratford, F.L., M. Ramjeesingh, J.C. Cheung, L.J. Huan, and C.E. Bear. 2007. The Walker B motif of the second nucleotide-binding domain (NBD2) of CFTR plays a key role in ATPase activity by the NBD1-NBD2 heterodimer. Biochem. J. 401:581-586. https :// doi .org /10 .1042 /BJ20060968
45. Thibodeau, P.H., C.A. Brautigam, M. Machius, and P.J. Thomas. 2005. Side chain and backbone contributions of Phe508 to CFTR folding. Nat. Struct. Mol. Biol. 12:10-16. https ://doi .org /10 .1038 /nsmb881
46. Tsai, M.F., H. Shimizu, Y. Sohma, M. Li, and T.C. Hwang. 2009. Statedependent modulation of CFTR gating by pyrophosphate. J. Gen. Physiol. 133:405-419. https ://doi .org /10 .1085 /jgp .200810186
47. Tsai, M.F., M. Li, and T.C. Hwang. 2010. Stable ATP binding mediated by a partial NBD dimer of the CFTR chloride channel. J. Gen. Physiol. 135:399-414. https ://doi .org /10 .1085 /jgp .201010399
48. Van Goor, F., S. Hadida, P.D. Grootenhuis, B. Burton, D. Cao, T. Neuberger, A. Turnbull, A. Singh, J. Joubran, A. Hazlewood, et al. 2009. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. USA. 106:18825-18830. https ://doi .org /10 .1073 /pnas .0904709106
49. Van Goor, F., S. Hadida, P.D. Grootenhuis, B. Burton, J.H. Stack, K.S. Straley, C.J. Decker, M. Miller, J. McCartney, E.R. Olson, et al. 2011. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. USA. 108:18843-18848. https ://doi .org /10 .1073 /pnas .1105787108
50. Van Goor, F., H. Yu, B. Burton, and B.J. Hoffman. 2014. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cyst. Fibros. 13:29-36. https ://doi .org /10 .1016 /j .jcf .2013 .06 .008
51. Veit, G., R.G. Avramescu, D. Perdomo, P.-W. Phuan, M. Bagdany, P.M. Apaja, F. Borot, D. Szollosi, Y.-S. Wu, W.E. Finkbeiner, et al. 2014. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci. Transl. Med. 6:246ra297. https ://doi .org /10 .1126 /scitranslmed .3008889
52. Veit, G., R.G. Avramescu, A.N. Chiang, S.A. Houck, Z. Cai, K.W. Peters, J.S. Hong, H.B. Pollard, W.B. Guggino, W.E. Balch, et al. 2016. From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations. Mol. Biol. Cell. 27:424-433. https ://doi .org /10 .1091 / mbc .E14-04-0935
53. Vergani, P., A.C. Nairn, and D.C. Gadsby. 2003. On the mechanism of MgATP-dependent gating of CFTR Cl-channels. J. Gen. Physiol. 121:17-36. https ://doi .org /10 .1085 /jgp .20028673
54. Vergani, P., S.W. Lockless, A.C. Nairn, and D.C. Gadsby. 2005. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature. 433:876-880. https ://doi .org /10 .1038 /nature03313
55. Wang, W., G. Li, J.P. Clancy, and K.L. Kirk. 2005. Activating cystic fibrosis transmembrane conductance regulator channels with pore blocker analogs. J. Biol. Chem. 280:23622-23630. https ://doi .org /10 .1074 /jbc .M503118200
56. Welsh, M.J., and A.E. Smith. 1993. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 73:1251-1254. https ://doi .org /10 .1016 /0092-8674(93)90353-R
57. Yang, H., A.A. Shelat, R.K. Guy, V.S. Gopinath, T. Ma, K. Du, G.L. Lukacs, A. Taddei, C. Folli, N. Pedemonte, et al. 2003. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J. Biol. Chem. 278:35079-35085. https :// doi .org /10 .1074 /jbc .M303098200
58. Yeh, H.I., J.T. Yeh, and T.C. Hwang. 2015. Modulation of CFTR gating by permeant ions. J. Gen. Physiol. 145:47-60. https ://doi .org /10 .1085 /jgp .201411272
59. Yu, H., B. Burton, C.J. Huang, J. Worley, D. Cao, J.P. Johnson Jr., A. Urrutia, J. Joubran, S. Seepersaud, K. Sussky, et al. 2012. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cyst. Fibros. 11:237-245. https ://doi .org /10 .1016 /j .jcf .2011 .12 .005
60. Zhou, Z., X. Wang, M. Li, Y. Sohma, X. Zou, and T.C. Hwang. 2005. High affinity ATP/ADP analogues as new tools for studying CFTR gating. J. Physiol. 569:447-457. https ://doi .org /10 .1113 /jphysiol .2005 .095083
61. Zielenski, J., and L.C. Tsui. 1995. Cystic fibrosis: Genotypic and phenotypic variations. Annu. Rev. Genet. 29:777-807. https ://doi .org /10 .1146 /annurev .ge .29 .120195 .004021